Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Meta Platforms (META) spreader of March 900 and 1100 calls as share price up in last three weeks
• Energy Select Sector SPDR ETF (XLE) call put ratio 1 call to 1 put amid energy price movement
• United States Oil Fund (USO) call put ratio 1 call to 1.6 puts as oil pulls back